DEXTROSE injection, solution

Dextrose by

Drug Labeling and Warnings

Dextrose by is a Prescription medication manufactured, distributed, or labeled by ICU Medical Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Dextrose Injection 20%, 30%, 40%, 50% and 70%, mixed with amino acids or other compatible intravenous fluids, is indicated as a source of calories for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Important Preparation and Administration Instructions

    Dextrose Injection is supplied in the following five strengths: 20%, 30%, 40%, 50% and 70% [see How Supplied/Storage and Handling (16)]. Prior to administration, Dextrose Injection must be diluted with other compatible intravenous fluids or used as an admixture with amino acids. It is not for direct intravenous infusion.

    Preparation Prior to Administration

    • Because additives may be incompatible, evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available. If it is deemed advisable to introduce additives, use aseptic technique and mix thoroughly.
    • Inspect Dextrose Injection to ensure precipitates have not formed during the mixing or addition of additives. Discard the bag if precipitates are observed. Some opacity of the plastic container (due to moisture absorption during sterilization process) may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.
    • Use promptly after admixing or dilution.
    • For single use only; discard unused portion

    Important Administration Instructions

    • Set the vent to the closed position on a vented intravenous administration set to prevent air embolism.
    • Use a dedicated line without any connections to avoid air embolism.
    • Prior to infusion, visually inspect the diluted dextrose solution for particulate matter. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear and container is undamaged.
    • The choice of a central or peripheral venous route of infusion should depend on the osmolarity of the final infusate. Solutions with greater than 5% dextrose or with osmolarity of greater than or equal to 900 mOsm/L must be infused through a central catheter [see Warnings and Precautions (5.5)].

    2.2 Dosing Information

    Caution: Dextrose Injection is not for direct intravenous infusion. Prior to administration, Dextrose Injection must be diluted with other compatible intravenous fluids or used as an admixture with amino acids.

    Individualize the dosage of Dextrose Injection based on the patient's clinical condition (ability to adequately metabolize dextrose), body weight, nutritional and fluid requirements, as well as additional energy given orally or enterally to the patient.

    The administration rate should be governed, especially during the first few day of therapy, by the patient's tolerance to dextrose. Daily intake of amino acids and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of blood glucose levels.

    2.3 Discontinuation of Dextrose Injection

    To reduce the risk of hypoglycemia, a gradual decrease in flow rate in the last hour of infusion should be considered.

  • 3 DOSAGE FORMS AND STRENGTHS

    Dextrose Injection 20%, 30%, 40%, 50%, and 70% USP are sterile, non-pyrogenic, hypertonic solutions of dextrose in single-dose, partial-fill, flexible containers.

    500 mL fill volume in 1000 mL flexible container

    • 20% (0.2 grams/mL): 20 grams of dextrose hydrous per 100 mL
    • 30% (0.3 grams/mL): 30 grams of dextrose hydrous per 100 mL
    • 40% (0.4 grams/mL): 40 grams of dextrose hydrous per 100 mL
    • 50% (0.5 grams/mL): 50 grams of dextrose hydrous per 100 mL
    • 70% (0.7 grams/mL): 70 grams of dextrose hydrous per 100 mL
  • 4 CONTRAINDICATIONS

    The use of Dextrose Injection is contraindicated in patients:

    • who are severely dehydrated as hypertonic dextrose solution can worsen the patient's hyperosmolar state.
    • with known hypersensitivity to dextrose [see Warnings and Precautions (5.2)].
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hyperglycemia and Hyperosmolar Hyperglycemic State

    The use of dextrose infusions in patients with diabetes mellitus or impaired glucose tolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma, and death. Patients with underlying confusion and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state. Monitor blood glucose levels and treat hyperglycemia to maintain optimum levels while administering Dextrose Injection. Insulin may be administered or adjusted to maintain optimal blood glucose levels during Dextrose Injection administration.

    5.2 Hypersensitivity Reactions

    Hypersensitivity reactions including anaphylaxis have been reported with dextrose infusions. Stop infusion immediately and treat patient accordingly if signs or symptoms of a hypersensitivity reaction develop. Signs or symptoms may include: tachypnea, dyspnea, hypoxia, bronchospasm, tachycardia, hypotension, cyanosis, vomiting, nausea, headache, sweating, dizziness, altered mentation, flushing, rash, urticaria, erythema, pyrexia, and chills.

    5.3 Risk of Infections

    Patients who require parenteral nutrition are at high risk of infections because the nutritional components of these solutions can support microbial growth. The risk of infection is increased in patients with malnutrition-associated immunosuppression, hyperglycemia exacerbated by dextrose infusion, long-term use and poor maintenance of intravenous catheters, or immunosuppressive effects of other concomitant conditions, drugs, or other components of the parenteral formulation (e.g., lipid emulsion).

    To decrease the risk of infectious complications, ensure aseptic technique in catheter placement and maintenance, as well as aseptic technique in the preparation and administration of the nutritional formula.

    Monitor for signs and symptoms (including fever and chills) of early infections, including laboratory test results (including leukocytosis and hyperglycemia) and frequent checks of the parenteral access device and insertion site for edema, redness and discharge.

    5.4 Refeeding Syndrome

    Refeeding severely undernourished patients may result in refeeding syndrome, characterized by the intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, monitor severely undernourished patients and slowly increase nutrient intakes.

    5.5 Vein Damage and Thrombosis

    Dextrose Injection is for admixture with amino acids or dilution with other compatible intravenous fluids. It is not for direct intravenous infusion. Administer solutions containing more than 5% dextrose or with an osmolarity of ≥ 900 mOsm/L through a central vein [see Dosage and Administration (2.1)]. The infusion of hypertonic solutions into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.

    5.6 Aluminum Toxicity

    Dextrose Injection contains no more than 25 mcg/L of aluminum. However, with prolonged parenteral administration in patients with renal impairment, the aluminum contained in Dextrose Injection may reach toxic levels. Preterm infants are at greater risk because their kidneys are immature, and they require large amounts of concomitant calcium and phosphate solutions that contain aluminum. Patients with renal impairment, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day, accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration of total parenteral nutrition products.

    5.7 Risk of Parenteral Nutrition Associated Liver Disease

    Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis. The exact etiology is not entirely clear and is likely multifactorial. If Dextrose Injection-treated patients develop abnormal liver function tests consider discontinuation or dosage reduction.

    5.8 Electrolyte Imbalance and Fluid Overload

    Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions.

    Depending on the volume and rate of infusion, the intravenous administration of concentrated dextrose solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations in the administered solution. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations in the solution.

    Monitor blood electrolyte levels, correct fluid and electrolyte imbalances, and administer essential vitamins and minerals as needed. Monitor daily fluid balance.

  • 6 ADVERSE REACTIONS

    The following adverse reactions from voluntary reports or clinical studies have been reported with Dextrose Injection. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    • Hyperglycemia and hyperosmolar hyperglycemic state [see Warnings and Precautions (5.1)].
    • Hypersensitivity reactions [see Warnings and Precautions (5.2)].
    • Risk of infections [see Warnings and Precautions (5.3)].
    • Refeeding syndrome [see Warnings and Precautions (5.4)].
    • Vein damage and thrombosis [see Warnings and Precautions (5.5)].
    • Aluminum toxicity [see Warnings and Precautions (5.6)].
    • Risk of parenteral nutrition associated liver disease [see Warnings and Precautions (5.7)].
    • Electrolyte imbalance and fluid overload [see Warnings and Precautions (5.8)].
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no data with Dextrose Injection in pregnant women. In addition, animal reproduction studies have not been conducted with dextrose. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    Clinical Considerations

    Disease-Associated Maternal and/or Embryo/Fetal Risk

    Consider parenteral nutrition in cases of severe maternal malnutrition where nutritional requirements cannot be fulfilled by the enteral route because of the risks to the fetus associated with severe malnutrition, including preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations, and perinatal mortality.

    8.2 Lactation

    There are no data regarding the presence of dextrose in human milk, the effects on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Dextrose Injection and any potential adverse effects on the breastfed infant from Dextrose Injection or from the underlying maternal condition.

    8.4 Pediatric Use

    Neonates, especially those born premature and with low birth weight are at increased risk of developing hypo – or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose infusions to ensure adequate glycemic control in order to avoid potential long term adverse effects. Hypoglycemia in the newborn can cause prolonged seizures, coma and brain damage. Hyperglycemia has been associated with intraventricular hemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, prolonged length of hospital stay, and death. Plasma electrolyte concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes. In very low birth weight infants, excessive or rapid administration of Dextrose Injection may result in increased serum osmolality and possible intracerebral hemorrhage.

    Because of immature renal function, preterm infants receiving prolonged treatment with Dextrose Injection, may be at risk aluminum toxicity [see Warnings and Precautions (5.6)].

    Patients, including pediatric patients, may be at risk for Parenteral Nutrition Associated Liver Disease (PNALD) [see Warnings and Precautions (5.7)].

    8.5 Geriatric Use

    Clinical studies of Dextrose Injection did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from other younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

  • 10 OVERDOSAGE

    An increased infusion rate of Dextrose Injection or administration of a concentrated dextrose solution can cause hyperglycemia, hyperosmolality, and adverse effects on water and electrolyte balance [see Warnings and Precautions (5.1, 5.8)].

    Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal.

    Discontinue infusion and institute appropriate corrective measures in the event of overhydration or solute overload during therapy, with particular attention to respiratory and cardiovascular systems.

    For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.

  • 11 DESCRIPTION

    Dextrose Injection, USP 20%, 30%, 40%, 50% and 70% are sterile, nonpyrogenic, hypertonic solutions of Dextrose, USP in Water for Injection in a polyvinylchloride flexible plastic container for intravenous administration after appropriate admixture or dilution [see Dosage and Administration (2.1)].

    Partial-fill containers, designed to facilitate admixture or dilution to provide dextrose in various concentrations, are available in various sizes. See Table 1 for the content and characteristics of these concentrated solutions. The solutions contain no bacteriostatic, antimicrobial agent or added buffer and are intended only for use as a single-dose injection following admixture or dilution. The pH is 4.3 (range is 3.2 to 6.5).

    Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly.

    Table 1. Contents and Characteristics of Dextrose Injection 20%, 30%, 40%, 50%, and 70%
  • * Caloric value calculated on the basis of 3.4 kcal/g of dextrose, hydrous.
  • Strength

    Fill Volume

    Amount of Dextrose Hydrous per Container

    kcal*
    per Container

    mOsmol
    per liter

    20% (0.2 grams/mL)

    500 mL

    100 grams

    340

    1009

    30% (0.3 grams/mL)

    500 mL

    150 grams

    510

    1514

    40% (0.4 grams/mL)

    500 mL

    200 grams

    680

    2018

    50% (0.5 grams/mL)

    500 mL

    250 grams

    850

    2523

    70% (0.7 grams/mL)

    500 mL

    350 grams

    1190

    3532

    Dextrose, USP is chemically designated D-glucose, monohydrate (C6H12O6 H2O), a hexose sugar freely soluble in water. The molecular weight of dextrose (D-glucose) monohydrate is 198.17. It has the following structural formula:

    Structural Formula for Dextrose Injection, USP

    Dextrose may be derived from corn.

    Water for Injection, USP is chemically designated H2O.

    Dextrose Injection contains no more than 25 mcg/L of aluminum.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Dextrose Injection is used to supplement nutrition by providing glucose parenterally. Dextrose is oxidized to carbon dioxide and water, yielding energy.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Dextrose Injection, 20%, 30%, 40%, 50%, and 70% USP are sterile hypertonic solutions of dextrose supplied in single-dose, partial-fill flexible containers (see Tables 1 and 2) for intravenous administration after appropriate admixture or dilution [see Dosage and Administration (2.1)].

    Do not remove container from the overwrap until intended for use.

    Table 2: Strengths, Fill Volume, and NDC # of Dextrose Injection 20%, 30%, 40%, 50%, and 70%

    Strength

    Fill Volume

    NDC#

    20% (0.2 grams/mL)

    500 mL

    0409-7935-19
    0990-7935-19

    30% (0.3 grams/mL)

    500 mL

    0409-8004-15
    0990-8004-15

    40% (0.4 grams/mL)

    500 mL

    0409-7937-19
    0990-7937-19

    50% (0.5 grams/mL)

    500 mL

    0409-7936-19
    0990-7936-19

    70% (0.7 grams/mL)

    500 mL

    0409-7918-19
    0990-7918-19

    ICU Medical is transitioning NDC codes from the "0409" to a "0990" labeler code. Both NDC codes are expected to be in the market for a period of time.

    Use the product immediately after mixing and the introduction of additives.

    Store between 20°C to 25°C (68°F to 77°F). [See USP controlled room temperature.]

    Do not freeze.

  • 17 PATIENT COUNSELING INFORMATION

    Inform patients, caregivers, or home healthcare providers of the following risks of Dextrose Injection:

    • Hyperglycemia and hyperosmolar hyperglycemic state [see Warnings and Precautions (5.1)]
    • Hypersensitivity reactions [see Warnings and Precautions (5.2)]
    • Risk of infection [see Warnings and Precautions (5.3)]
    • Vein damage and thrombosis [see Warnings and Precautions (5.5)]
    • Aluminum toxicity [see Warnings and Precautions (5.6)]
    • Risk of parenteral nutrition associated liver disease [see Warnings and Precautions (5.7)]
    • Fluid overload and electrolyte imbalance [see Warnings and Precautions (5.8)]



                                                                                    EN-4695

    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

  • PRINCIPAL DISPLAY PANEL - 70 g/100 mL Bag Label

    500 mL
    NDC: 0990-7918-19

    DEXTROSE
    INJECTION,
    USP

    70%

    IN 1000 mL PARTIAL-FILL CONTAINER
    EACH 100 mL CONTAINS DEXTROSE, HYDROUS, USP
    70 g IN WATER FOR INJECTION.
    HYPERTONIC OSMOLARITY 3532 mOsmol/LITER (calc).
    pH 4.3 (3.2 to 6.5)
    SPECIFIC GRAVITY 1.236
    CAUTION: HYPERTONIC. ADMINISTER ONLY AFTER
    DILUTION VIA CENTRAL VENOUS CATHETER.

    STERILE, NONPYROGENIC. SINGLE DOSE CONTAINER.
    DOSAGE AND ADMINISTRATION: SEE PACKAGE
    INSERT.
    CAUTION: DO NOT USE UNLESS SOLUTION IS CLEAR,
    CLOSURE IS INTACT, AND CONTAINER IS
    UNDAMAGED. CHECK FOR MINUTE LEAKS BY
    SQUEEZING FIRMLY. IF LEAKS ARE FOUND DISCARD
    CONTAINER AND CONTENTS AS STERILITY MAY BE
    IMPAIRED. MUST NOT BE USED IN SERIES
    CONNECTIONS.

    ADDITIVES MAY BE INCOMPATIBLE. CONSULT
    WITH PHARMACIST, IF AVAILABLE. WHEN
    INTRODUCING ADDITIVES, USE ASEPTIC
    TECHNIQUE, MIX THOROUGHLY AND DO NOT
    STORE.

    RECOMMENDED STORAGE: ROOM TEMPERATURE
    (25°C/77°F). AVOID EXCESSIVE HEAT. PROTECT FROM
    FREEZING.
    Rx ONLY

    IM-4402

    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

    3
    v

    CONTAINS DEHP

    70%

    icumedical

    PPRINCIPAL DISPLAY PANEL - 70 g/100 mL Bag Label
  • PRINCIPAL DISPLAY PANEL - 70 g/100 mL Bag Overwrap

    TO OPEN — TEAR AT NOTCH

    The overwrap is a moisture and oxygen barrier. Do not remove
    unit from overwrap until ready for use. Visually inspect
    overwrap for tears or holes. Discard unit if overwrap is
    damaged. Use unit promptly when pouch is opened. Store at
    20 to 25°C (68 to 77°F). [See USP Controlled Room
    Temperature.] Protect from freezing. See insert. After
    removing the overwrap, check for minute leaks by squeezing
    container firmly. If leaks are found, discard solution as sterility
    may be impaired.

    Rx only

    WR-0551

    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

    icumedical

    PRINCIPAL DISPLAY PANEL - 70 g/100 mL Bag Overwrap
  • PRINCIPAL DISPLAY PANEL - 20 g/100 mL Bag Label

    500 mL
    IN 1000 mL PARTIAL-FILL CONTAINER

    NDC: 0990-7935-19

    20% DEXTROSE
    Injection, USP

    EACH 100 mL CONTAINS DEXTROSE,
    HYDROUS 20 g IN WATER FOR INJECTION.
    1009 mOsmol/LITER (CALC.)
    pH 4.3 (3.2 to 6.5)
    CAUTION: HYPERTONIC. ADMINISTER
    ONLY AFTER DILUTION.
    DEXTROSE
    SOLUTIONS WITHOUT SALTS SHOULD
    NOT BE USED IN BLOOD TRANSFUSIONS
    BECAUSE OF POSSIBLE ROULEAU
    FORMATION.

    ADDITIVES MAY BE INCOMPATIBLE.
    CONSULT WITH PHARMACIST, IF
    AVAILABLE. WHEN INTRODUCING
    ADDITIVES, USE ASEPTIC
    TECHNIQUE, MIX THOROUGHLY AND
    DO NOT STORE.

    SINGLE-DOSE CONTAINER. FOR
    INTRAVENOUS USE. USUAL DOSAGE:
    SEE INSERT. STERILE, NONPYROGENIC.
    USE ONLY IF SOLUTION IS CLEAR AND
    CONTAINER IS UNDAMAGED. MUST
    NOT BE USED IN SERIES CONNECTIONS.

    Rx ONLY

    3
    v

    CONTAINS DEHP

    icumedical

    IM-4404
    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

    PRINCIPAL DISPLAY PANEL - 20 g/100 mL Bag Label
  • PRINCIPAL DISPLAY PANEL - 20 g/100 mL Bag Overwrap

    TO OPEN — TEAR AT NOTCH

    The overwrap is a moisture and oxygen barrier. Do not remove
    unit from overwrap until ready for use. Visually inspect
    overwrap for tears or holes. Discard unit if overwrap is
    damaged. Use unit promptly when pouch is opened.
    Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room
    Temperature.] Protect from freezing. See insert. After removing
    the overwrap, check for minute leaks by squeezing container
    firmly. If leaks are found, discard solution as sterility may be
    impaired.

    Rx only

    WR-0552

    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

    icumedical

    PRINCIPAL DISPLAY PANEL - 20 g/100 mL Bag Overwrap
  • PRINCIPAL DISPLAY PANEL - 50 g/100 mL Bag Label

    500 mL
    NDC: 0990-7936-19

    DEXTROSE
    INJECTION,
    USP

    50%

    IN 1000 mL PARTIAL-FILL CONTAINER
    EACH 100 mL CONTAINS DEXTROSE, HYDROUS, USP
    50 g IN WATER FOR INJECTION.
    HYPERTONIC OSMOLARITY 2523 mOsmol/LITER (calc).
    pH 4.3 (3.2 to 6.5)
    SPECIFIC GRAVITY 1.170
    CAUTION: HYPERTONIC. ADMINISTER ONLY AFTER
    DILUTION VIA CENTRAL VENOUS CATHETER.

    STERILE, NONPYROGENIC. SINGLE DOSE CONTAINER.
    DOSAGE AND ADMINISTRATION: SEE PACKAGE
    INSERT.
    CAUTION: DO NOT USE UNLESS SOLUTION IS
    CLEAR, CLOSURE IS INTACT, AND CONTAINER IS
    UNDAMAGED. CHECK FOR MINUTE LEAKS BY
    SQUEEZING FIRMLY. IF LEAKS ARE FOUND DISCARD
    CONTAINER AND CONTENTS AS STERILITY MAY
    BE IMPAIRED. MUST NOT BE USED IN SERIES
    CONNECTIONS.

    ADDITIVES MAY BE INCOMPATIBLE. CONSULT
    WITH PHARMACIST, IF AVAILABLE. WHEN
    INTRODUCING ADDITIVES, USE ASEPTIC
    TECHNIQUE, MIX THOROUGHLY AND DO NOT
    STORE.

    RECOMMENDED STORAGE: ROOM TEMPERATURE
    (25°C/77°F). AVOID EXCESSIVE HEAT. PROTECT FROM
    FREEZING.

    Rx ONLY

    IM-4433
    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

    3
    v

    CONTAINS DEHP

    50%

    icumedical

    PRINCIPAL DISPLAY PANEL - 50 g/100 mL Bag Label
  • PRINCIPAL DISPLAY PANEL - 50 g/100 mL Bag Overwrap

    TO OPEN — TEAR AT NOTCH

    The overwrap is a moisture and oxygen barrier. Do not remove
    unit from overwrap until ready for use. Visually inspect
    overwrap for tears or holes. Discard unit if overwrap is
    damaged. Use unit promptly when pouch is opened. Store at
    20 to 25°C (68 to 77°F). [See USP Controlled Room
    Temperature.] Protect from freezing. See insert. After
    removing the overwrap, check for minute leaks by squeezing
    container firmly. If leaks are found, discard solution as sterility
    may be impaired.

    Rx only

    WR-0555

    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

    icumedical

    PRINCIPAL DISPLAY PANEL - 50 g/100 mL Bag Overwrap
  • PRINCIPAL DISPLAY PANEL - 40 g/100 mL Bag Label

    500 mL
    IN 1000 mL PARTIAL-FILL CONTAINER

    NDC: 0990-7937-19

    40% DEXTROSE
    Injection, USP

    EACH 100 mL CONTAINS DEXTROSE,
    HYDROUS 40 g IN WATER FOR INJECTION.
    2018 mOsmol/LITER (CALC.)
    pH 4.3 (3.2 to 6.5)
    CAUTION: HYPERTONIC. ADMINISTER ONLY
    AFTER DILUTION VIA CENTRAL VENOUS
    CATHETER.
    DEXTROSE SOLUTIONS
    WITHOUT SALTS SHOULD NOT BE USED
    IN BLOOD TRANSFUSIONS BECAUSE OF
    POSSIBLE ROULEAU FORMATION.

    ADDITIVES MAY BE INCOMPATIBLE.
    CONSULT WITH PHARMACIST, IF
    AVAILABLE. WHEN INTRODUCING
    ADDITIVES, USE ASEPTIC TECHNIQUE,
    MIX THOROUGHLY AND DO NOT STORE.

    SINGLE-DOSE CONTAINER. FOR
    INTRAVENOUS USE. USUAL DOSAGE: SEE
    INSERT. STERILE, NONPYROGENIC. USE
    ONLY IF SOLUTION IS CLEAR AND
    CONTAINER IS UNDAMAGED. MUST NOT
    BE USED IN SERIES CONNECTIONS.

    Rx ONLY

    3
    v

    CONTAINS DEHP

    icumedical

    IM-4434
    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

    PRINCIPAL DISPLAY PANEL - 40 g/100 mL Bag Label
  • PRINCIPAL DISPLAY PANEL - 40 g/100 mL Bag Overwrap

    TO OPEN — TEAR AT NOTCH

    The overwrap is a moisture and oxygen barrier. Do not remove
    unit from overwrap until ready for use. Visually inspect
    overwrap for tears or holes. Discard unit if overwrap is
    damaged. Use unit promptly when pouch is opened. Store at
    20 to 25°C (68 to 77°F). [See USP Controlled Room
    Temperature.] Protect from freezing. See insert. After removing
    the overwrap, check for minute leaks by squeezing container
    firmly. If leaks are found, discard solution as sterility may be
    impaired.

    Rx only

    WR-0557

    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

    icumedical

    PRINCIPAL DISPLAY PANEL - 40 g/100 mL Bag Overwrap
  • PRINCIPAL DISPLAY PANEL - 30 g/100 mL Bag Label

    500 mL
    IN 1000 mL PARTIAL-FILL CONTAINER

    NDC: 0990-8004-15

    30% DEXTROSE
    Injection, USP

    EACH 100 mL CONTAINS DEXTROSE,
    HYDROUS 30 g IN WATER FOR INJECTION.
    1514 mOsmol/LITER (CALC.)
    pH 4.3 (3.2 to 6.5)
    CAUTION: HYPERTONIC. ADMINISTER
    ONLY AFTER DILUTION VIA CENTRAL
    VENOUS CATHETER.
    DEXTROSE
    SOLUTIONS WITHOUT SALTS SHOULD
    NOT BE USED IN BLOOD TRANSFUSIONS
    BECAUSE OF POSSIBLE ROULEAU
    FORMATION.

    ADDITIVES MAY BE INCOMPATIBLE.
    CONSULT WITH PHARMACIST, IF
    AVAILABLE. WHEN INTRODUCING
    ADDITIVES, USE ASEPTIC TECHNIQUE,
    MIX THOROUGHLY AND DO NOT
    STORE.

    SINGLE-DOSE CONTAINER. FOR
    INTRAVENOUS USE. USUAL DOSAGE:
    SEE INSERT. STERILE, NONPYROGENIC.
    USE ONLY IF SOLUTION IS CLEAR AND
    CONTAINER IS UNDAMAGED. MUST
    NOT BE USED IN SERIES CONNECTIONS.

    Rx ONLY

    3
    v

    CONTAINS DEHP

    IM-4436
    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

    icumedical

    PRINCIPAL DISPLAY PANEL - 30 g/100 mL Bag Label
  • PRINCIPAL DISPLAY PANEL - 30 g/100 mL Bag Overwrap

    TO OPEN — TEAR AT NOTCH

    The overwrap is a moisture and oxygen barrier. Do not remove
    unit from overwrap until ready for use. Visually inspect
    overwrap for tears or holes. Discard unit if overwrap is
    damaged. Use unit promptly when pouch is opened. Store at
    20 to 25°C (68 to 77°F). [See USP Controlled Room
    Temperature.] Protect from freezing. See insert. After removing
    the overwrap, check for minute leaks by squeezing container
    firmly. If leaks are found, discard solution as sterility may be
    impaired.

    Rx only

    WR-0560

    ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

    icumedical

    PRINCIPAL DISPLAY PANEL - 30 g/100 mL Bag Overwrap
  • INGREDIENTS AND APPEARANCE
    DEXTROSE 
    dextrose injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0990-7918
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK) DEXTROSE MONOHYDRATE70 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0990-7918-1912 in 1 CASE10/01/2019
    11 in 1 POUCH
    1500 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01856110/01/2019
    DEXTROSE 
    dextrose injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0990-7935
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK) DEXTROSE MONOHYDRATE20 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0990-7935-1912 in 1 CASE10/01/2019
    11 in 1 POUCH
    1500 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01856410/01/2019
    DEXTROSE 
    dextrose injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0990-7936
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK) DEXTROSE MONOHYDRATE50 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0990-7936-1912 in 1 CASE10/01/2019
    11 in 1 POUCH
    1500 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01856310/01/2019
    DEXTROSE 
    dextrose injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0990-7937
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK) DEXTROSE MONOHYDRATE40 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0990-7937-1912 in 1 CASE10/01/2019
    11 in 1 POUCH
    1500 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01856210/01/2019
    DEXTROSE 
    dextrose injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0990-8004
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK) DEXTROSE MONOHYDRATE30 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0990-8004-1512 in 1 CASE10/01/2019
    11 in 1 POUCH
    1500 mL in 1 BAG; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01934510/01/2019
    Labeler - ICU Medical Inc. (118380146)

  • © 2020 FDA.report
    This site is not affiliated with or endorsed by the FDA.